Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Clarithromycin | Case report

Pathogenicity of Mycolicibacterium phlei, a non-pathogenic nontuberculous mycobacterium in an immunocompetent host carrying anti-interferon gamma autoantibodies: a case report

Authors: Satomi Tanaka, Yoshihiko Hoshino, Takuro Sakagami, Hanako Fukano, Yohei Matsui, Osamu Hiranuma

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

Mycolicibacterium phlei (M. phlei) is known to be a non-pathogenic nontuberculous mycobacterium (NTM) which rarely causes diseases in humans. A disseminated NTM infection is mostly caused by the Mycobacterium avium complex (MAC) and is known to develop in immunocompromised hosts, like those with acquired immune deficiency syndrome (AIDS). Here, we report a case of disseminated M. phlei infection in an immunocompetent host carrying anti-interferon gamma (IFN-γ) autoantibodies.

Case presentation

We detected M. phlei in multiple organs of an elderly woman with no significant medical history except positivity for anti-IFN-γ autoantibodies. She tested negative for human immunodeficiency virus (HIV)-1, 2/ Human T-cell leukemia virus type 1 (HTLV-1) antibody. High-resolution computed tomography (HRCT) of the chest demonstrated a nodule in the left S1 + 2 segment, interlobular septal thickening, multi lymphadenopathy, and osteolysis. A maximum intensity projection image following fluorodeoxyglucose-positron emission tomography (FDG-PET) revealed multifocal hypermetabolic lesions in the nodule and all the swollen lymph nodes seen in HRCT. FDG also accumulated in multiple bones. Advanced primary lung cancer was suspected, and biopsies of each lesion were performed. The pathology revealed caseating granuloma, positive for acid-fast bacteria, and DNA sequencing of the acid-fast bacteria confirmed the organism to be M. phlei. The patient also tested positive for anti-IFN-γ autoantibodies. Based on these findings, she was diagnosed with disseminated M. phlei infection, with anti-IFN-γ autoantibodies.

Conclusions

Though known to be non-pathogenic, we show that M. phlei can be pathogenic like the MAC in immunocompetent individuals carrying anti-IFN-γ autoantibodies.
Literature
1.
go back to reference Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, Kirk JL, Jutivorakool K, Zaman R, Ding L, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367(8):725–34.CrossRef Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, Kirk JL, Jutivorakool K, Zaman R, Ding L, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367(8):725–34.CrossRef
2.
go back to reference Aguilar JL, Sanchez EE, Carrillo C, Alarcon GS, Silicani A. Septic arthritis due to Mycobacterium phlei presenting as infantile Reiter's syndrome. J Rheumatol. 1989;16(10):1377–8.PubMed Aguilar JL, Sanchez EE, Carrillo C, Alarcon GS, Silicani A. Septic arthritis due to Mycobacterium phlei presenting as infantile Reiter's syndrome. J Rheumatol. 1989;16(10):1377–8.PubMed
3.
go back to reference Spiegl PV, Feiner CM. Mycobacterium phlei infection of the foot: a case report. Foot Ankle Int. 1994;15(12):680–3.CrossRef Spiegl PV, Feiner CM. Mycobacterium phlei infection of the foot: a case report. Foot Ankle Int. 1994;15(12):680–3.CrossRef
4.
go back to reference Paul E, Devarajan P. Mycobacterium phlei peritonitis: a rare complication of chronic peritoneal dialysis. Pediatr Nephrol. 1998;12(1):67–8.CrossRef Paul E, Devarajan P. Mycobacterium phlei peritonitis: a rare complication of chronic peritoneal dialysis. Pediatr Nephrol. 1998;12(1):67–8.CrossRef
5.
go back to reference Karnam S, Alla VM, Kwon J, Harbert T, Sharma A, Airey K, Mooss A. Mycobacterium phlei, a previously unreported cause of pacemaker infection: thinking outside the box in cardiac device infections. Cardiol J. 2011;18(6):687–90.CrossRef Karnam S, Alla VM, Kwon J, Harbert T, Sharma A, Airey K, Mooss A. Mycobacterium phlei, a previously unreported cause of pacemaker infection: thinking outside the box in cardiac device infections. Cardiol J. 2011;18(6):687–90.CrossRef
6.
go back to reference Shojaei H, Heidarieh P, Hashemi A, Feizabadi MM, Daei Naser A. Species identification of neglected nontuberculous mycobacteria in a developing country. Jpn J Infect Dis. 2011;64(4):265–71.PubMed Shojaei H, Heidarieh P, Hashemi A, Feizabadi MM, Daei Naser A. Species identification of neglected nontuberculous mycobacteria in a developing country. Jpn J Infect Dis. 2011;64(4):265–71.PubMed
7.
go back to reference Lima CA, Gomes HM, Oelemann MA, Ramos JP, Caldas PC, Campos CE, Pereira MA, Montes FF, Oliveira Mdo S, Suffys PN, et al. Nontuberculous mycobacteria in respiratory samples from patients with pulmonary tuberculosis in the state of Rondonia, Brazil. Mem Inst Oswaldo Cruz. 2013;108(4):457–62.CrossRef Lima CA, Gomes HM, Oelemann MA, Ramos JP, Caldas PC, Campos CE, Pereira MA, Montes FF, Oliveira Mdo S, Suffys PN, et al. Nontuberculous mycobacteria in respiratory samples from patients with pulmonary tuberculosis in the state of Rondonia, Brazil. Mem Inst Oswaldo Cruz. 2013;108(4):457–62.CrossRef
8.
go back to reference Khatter S, Singh UB, Arora J, Rana T, Seth P. Mycobacterial infections in human immuno-deficiency virus seropositive patients: role of non-tuberculous mycobacteria. Indian J Tuberc. 2008;55(1):28–33.PubMed Khatter S, Singh UB, Arora J, Rana T, Seth P. Mycobacterial infections in human immuno-deficiency virus seropositive patients: role of non-tuberculous mycobacteria. Indian J Tuberc. 2008;55(1):28–33.PubMed
9.
go back to reference Zhang J, Li C, Guo S. Effects of inhaled inactivated Mycobacterium phlei on airway inflammation in mouse asthmatic models. J Aerosol Med Pulm Drug Deliv. 2012;25(2):96–103.CrossRef Zhang J, Li C, Guo S. Effects of inhaled inactivated Mycobacterium phlei on airway inflammation in mouse asthmatic models. J Aerosol Med Pulm Drug Deliv. 2012;25(2):96–103.CrossRef
10.
go back to reference Kitada S, Kobayashi K, Ichiyama S, Takakura S, Sakatani M, Suzuki K, Takashima T, Nagai T, Sakurabayashi I, Ito M, et al. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med. 2008;177(7):793–7.CrossRef Kitada S, Kobayashi K, Ichiyama S, Takakura S, Sakatani M, Suzuki K, Takashima T, Nagai T, Sakurabayashi I, Ito M, et al. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med. 2008;177(7):793–7.CrossRef
11.
go back to reference Shima K, Sakagami T, Tanabe Y, Aoki N, Moro H, Koya T, Kagamu H, Hasegawa T, Suzuki E, Narita I. Novel assay to detect increased level of neutralizing anti-interferon gamma autoantibodies in non-tuberculous mycobacterial patients. J Infect Chemother. 2014;20(1):52–6.CrossRef Shima K, Sakagami T, Tanabe Y, Aoki N, Moro H, Koya T, Kagamu H, Hasegawa T, Suzuki E, Narita I. Novel assay to detect increased level of neutralizing anti-interferon gamma autoantibodies in non-tuberculous mycobacterial patients. J Infect Chemother. 2014;20(1):52–6.CrossRef
12.
go back to reference Hase I, Morimoto K, Sakagami T, Kazumi Y, Ishii Y, van Ingen J. Disseminated Mycobacterium gordonae and Mycobacterium mantenii infection with elevated anti-IFN-gamma neutralizing autoantibodies. J Infect Chemother. 2015;21(6):468–72.CrossRef Hase I, Morimoto K, Sakagami T, Kazumi Y, Ishii Y, van Ingen J. Disseminated Mycobacterium gordonae and Mycobacterium mantenii infection with elevated anti-IFN-gamma neutralizing autoantibodies. J Infect Chemother. 2015;21(6):468–72.CrossRef
13.
go back to reference Runyon EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am. 1959;43(1):273–90.CrossRef Runyon EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am. 1959;43(1):273–90.CrossRef
14.
go back to reference Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical section of the American Lung Association. Am J Respir Crit Care Med 1997, 156(2 Pt 2):S1–25. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical section of the American Lung Association. Am J Respir Crit Care Med 1997, 156(2 Pt 2):S1–25.
15.
go back to reference Beltan E, Horgen L, Rastogi N. Secretion of cytokines by human macrophages upon infection by pathogenic and non-pathogenic mycobacteria. Microb Pathog. 2000;28(5):313–8.CrossRef Beltan E, Horgen L, Rastogi N. Secretion of cytokines by human macrophages upon infection by pathogenic and non-pathogenic mycobacteria. Microb Pathog. 2000;28(5):313–8.CrossRef
16.
go back to reference Raynaud C, Etienne G, Peyron P, Laneelle MA, Daffe M. Extracellular enzyme activities potentially involved in the pathogenicity of Mycobacterium tuberculosis. Microbiology. 1998;144(Pt 2):577–87.CrossRef Raynaud C, Etienne G, Peyron P, Laneelle MA, Daffe M. Extracellular enzyme activities potentially involved in the pathogenicity of Mycobacterium tuberculosis. Microbiology. 1998;144(Pt 2):577–87.CrossRef
17.
go back to reference Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin Immunol. 2014;26(6):454–70.CrossRef Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin Immunol. 2014;26(6):454–70.CrossRef
Metadata
Title
Pathogenicity of Mycolicibacterium phlei, a non-pathogenic nontuberculous mycobacterium in an immunocompetent host carrying anti-interferon gamma autoantibodies: a case report
Authors
Satomi Tanaka
Yoshihiko Hoshino
Takuro Sakagami
Hanako Fukano
Yohei Matsui
Osamu Hiranuma
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4050-z

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.